Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 100.99% | -287.57% | -198.67% | -854.66% | -9.12% |
| Total Depreciation and Amortization | -0.96% | 2.02% | 4.65% | 3.49% | -9.38% |
| Total Amortization of Deferred Charges | 40.00% | 27.14% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -76.55% | 849.07% | -36.69% | 265.18% | 149.34% |
| Change in Net Operating Assets | -124.82% | -85.29% | -1,801.20% | 231.79% | 53.34% |
| Cash from Operations | -59.91% | -119.31% | -123.82% | -22.57% | 60.62% |
| Capital Expenditure | 63.73% | -305.53% | -58.22% | -187.95% | -253.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.57% | -25.54% | 1,281.48% | -- | -- |
| Cash from Investing | 56.08% | -177.06% | 173.28% | -178.13% | -351.49% |
| Total Debt Issued | -100.00% | 225.00% | 205.00% | 66.67% | -- |
| Total Debt Repaid | 69.23% | 73.33% | 17.57% | 18.84% | -30.00% |
| Issuance of Common Stock | -21.84% | -- | -69.52% | -85.58% | -10.82% |
| Repurchase of Common Stock | 75.00% | -- | 95.93% | 69.87% | -349.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 67.03% | 176.51% | 107.45% | 63.53% | -50.77% |
| Foreign Exchange rate Adjustments | -98.36% | 290.72% | 123.53% | -304.05% | 47.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.39% | -48.72% | -138.69% | 96.11% | -66.19% |